|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.22 USD | +1.06% |
|
+51.81% | +52.19% |
Company Valuation: Revolution Medicines, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,628 | 1,855 | 2,115 | 4,720 | 8,083 | 23,434 | 23,434 | - |
| Change | - | -29.43% | 14.03% | 123.15% | 71.26% | 189.92% | 0% | - |
| Enterprise Value (EV) 1 | 2,628 | 1,278 | 1,470 | 2,867 | 5,794 | 23,163 | 23,434 | 23,070 |
| Change | - | -51.38% | 15.06% | 95.01% | 102.1% | 299.79% | 1.17% | -1.55% |
| P/E ratio | -19.7x | -9.79x | -7.73x | -7.43x | -12.2x | -21.7x | -19.4x | -23.4x |
| PBR | 4.58x | 3.1x | 3.14x | 1.78x | 3.24x | 14.8x | 25x | 540x |
| PEG | - | -0.4x | -0.4x | -0.3x | 1.68x | -0.4x | -1.6x | 1.4x |
| Capitalization / Revenue | 61.1x | 63.1x | 59.8x | 408x | - | 6,372x | 736x | 93.7x |
| EV / Revenue | 61.1x | 43.5x | 41.6x | 248x | - | 6,298x | 736x | 92.2x |
| EV / EBITDA | -24.3x | -6.91x | -5.81x | -5.96x | -8.5x | -20.6x | -17.8x | -19.2x |
| EV / EBIT | -23.7x | -6.8x | -5.69x | -5.88x | -8.4x | -20.3x | -17.9x | -19.9x |
| EV / FCF | -25.5x | -8.31x | -6.25x | -8x | -10.2x | -23.7x | -19.1x | -19.2x |
| FCF Yield | -3.92% | -12% | -16% | -12.5% | -9.8% | -4.23% | -5.22% | -5.21% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.01 | -2.57 | -3.08 | -3.86 | -3.58 | -5.587 | -6.253 | -5.18 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 42.98 | 29.39 | 35.38 | 11.58 | - | 3.678 | 31.84 | 250.1 |
| EBITDA 1 | -108.1 | -184.9 | -253.2 | -481.1 | -681.9 | -1,126 | -1,316 | -1,199 |
| EBIT 1 | -110.7 | -188 | -258.3 | -487.2 | -689.5 | -1,139 | -1,309 | -1,158 |
| Net income 1 | -110.4 | -187.1 | -248.7 | -436.4 | -600.1 | -1,064 | -1,234 | -1,062 |
| Net Debt 1 | - | -577.1 | -644.9 | -1,853 | -2,289 | -271.7 | - | -364 |
| Reference price 2 | 39.59 | 25.17 | 23.82 | 28.68 | 43.74 | 121.22 | 121.22 | 121.22 |
| Nbr of stocks (in thousands) | 66,380 | 73,687 | 88,791 | 164,565 | 184,795 | 193,320 | 193,320 | - |
| Announcement Date | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | 26/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -21.47x | 6231.22x | -20.36x | -.--% | 23.19B | |
| 38.98x | 5.66x | 18.94x | 0.88% | 49.13B | |
| 34.02x | 3.37x | 14.4x | -.--% | 41.14B | |
| 107.41x | 6.89x | 69.31x | -.--% | 38.85B | |
| 58.35x | 11.95x | 33.22x | 0.33% | 32.74B | |
| 41.11x | 6.66x | 30.29x | -.--% | 17.14B | |
| 28.5x | 2.26x | 10.11x | 0.85% | 15.04B | |
| 27.2x | 2.11x | 10.77x | -.--% | 14B | |
| -35.02x | 13.31x | -35.72x | -.--% | 12.87B | |
| Average | 31.01x | 698.16x | 14.55x | 0.23% | 27.12B | |
| Weighted average by Cap. | 40.81x | 597.80x | 21.28x | 0.27% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- RVMD Stock
- Valuation Revolution Medicines, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition